Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting.

IF 1.8 4区医学 Q3 ONCOLOGY Oncology-New York Pub Date : 2024-03-01 DOI:10.46883/2024.25921014

Fiza Khan, Foorquan Hashmi, Nerses Ghahramanyan, Elen Baloyan, Gevorg Tamamyan, Marina Konopleva, Naveen Pemmaraju, Astghik Voskanyan

引用次数: 0

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options and poor prognosis. This case report presents the clinical course and management of a 62-year-old man with BPDCN in a resource-limited setting. The patient presented with constitutional symptoms and abnormal complete blood count findings. Initial treatment was performed with an acute lymphoblastic leukemia-based chemotherapy regimen, and the patient achieved complete remission, but the disease recurred 7 months after the initial diagnosis was confirmed in April 2022. The subsequent therapy was not effective, and the patient died during treatment. This case highlights the challenges in managing BPDCN and the need for further research to improve outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在资源有限的环境中诊断和治疗痉挛性浆细胞树突状细胞肿瘤。

大疱性浆细胞树突状细胞瘤（BPDCN）是一种罕见的侵袭性血液恶性肿瘤，治疗方案有限，预后较差。本病例报告介绍了一名资源有限的 62 岁男性 BPDCN 患者的临床过程和治疗情况。患者表现为全身症状和全血细胞计数异常。患者最初接受了以急性淋巴细胞白血病为基础的化疗方案，并获得了完全缓解，但在2022年4月确诊后7个月病情复发。随后的治疗效果不佳，患者在治疗期间死亡。这一病例凸显了治疗 BPDCN 所面临的挑战，以及进一步研究改善预后的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology-New York 肿瘤学-肿瘤学

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

期刊最新文献

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors. Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care. Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia. Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs. A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation.